Q2 2010

Source filing unavailable

Q2 2010 · —

Revenue

$3.21M

no prior Q2 2009 on file

Net Income

-$12.15M

no prior Q2 2009 on file

EPS Diluted

-$0.13

no prior Q2 2009 on file

Operating Income-$12,152,078—

Margins · derived

Operating margin-378.2%

Net margin-378.1%

Same quarter

no prior Q2 2009 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR